Aarey Drugs & Pharmaceuticals PE ratio history and valuation
NSE: AAREYDRUGSBSE: 524412Pharmaceuticals & BiotechnologySmall Cap
Aarey Drugs & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Aug 2021 on NSE
Last close ₹108.05up ₹1.47 (1.38%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹106.58.
28 Oct: open ₹102.11, high ₹109.70, low ₹102.11
52-week range of traded prices to 28 Oct 2026
₹50.31Low, 30 Mar 2026₹114.80High, 19 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹344 Cr2,366th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,40,50858.3% delivered
Aarey Drugs & Pharmaceuticals' price to sales and dividend yield on 28 Oct 2026. Each gets a history once a year of trading is on record. Its P/E is not shown: the figures it needs for the twelve months to Jun 2026 are not complete or not comparable.
Aarey Drugs & Pharmaceuticals PE ratio and valuation against its own history
- Price to earningsA results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to bookThe share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.0.83today
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.The share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to book =Market cap÷Net worthNet worth. Shareholders' equity in the latest balance sheet. Net worth in the glossary₹150 Cr
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹415 Cr
- Enterprise value =Market cap+BorrowingsBorrowings. Total borrowings in the latest balance sheet. Borrowings in the glossary₹50 Cr−CashCash. Cash and bank balances in the latest balance sheet.₹1.40 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹6.79 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.3,18,74,303at 30 Sep 2026
Standalone accounts, the twelve months to Jun 2026, balance sheet at Mar 2026, ₹ crore.Aarey Drugs & Pharmaceuticals financials ›
Aarey Drugs & Pharmaceuticals valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 179 | 108 | 68 | 31 | 54 | 105 | 61 | 111 | 95 | 144 |
| Price to earnings | No full year | 16.1 | 10.2 | 5.6 | Earlier quarters restated in the year | 12.1 | Earlier quarters restated in the year | No full year | 16.7 | 34.7 |
| Price to book | No balance sheet | No balance sheet | 0.8 | 0.3 | 0.6 | Shares changed | 0.5 | 0.9 | 0.7 | 1.0 |
| Price to sales | No full year | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | No full year | 0.2 | 0.4 |
| EV to EBITDA | No full year | No balance sheet | 11.0 | 7.8 | 33.2 | Shares changed | 12.0 | No full year | 23.3 | Operating loss |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | No full year | 6.2% | 9.8% | 17.8% | Earlier quarters restated in the year | 8.3% | Earlier quarters restated in the year | No full year | 6.0% | 2.9% |
A ratio that does not exist on the day says why in its cell.
Aarey Drugs & Pharmaceuticals market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Dividends and the public's market cap
From the close on 28 Oct 2026.
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹202 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Aarey Drugs & Pharmaceuticals is 113th among them by market cap. Each median leaves out Aarey Drugs & Pharmaceuticals itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.1Across 157 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 2.9Across 190 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.2Across 144 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.49%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Haleos LabsHALEOSLABS | 439 | 27.75 | 2.05 | 13.3 | 0.10% |
 Infinium PharmachemINFINIUM | 429 | 35.28 | 3.54 | – | 0.00% |
 Jenburkt PharmaceuticalsJENBURPH | 387 | 11.78 | 1.96 | 8.2 | 2.36% |
 Medicamen BiotechMEDICAMEQ | 358 | – | 1.30 | 19.2 | 0.39% |
| Aarey Drugs & PharmaceuticalsAAREYDRUGS | 344 | – | – | – | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.19 | 5.94 | – | 0.00% |
 Lyka LabsLYKALABS | 280 | – | 3.03 | – | 0.00% |
 Astal LaboratoriesASTALLTD | 276 | 28.38 | 0.83 | 19.1 | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 272 | 20.09 | 1.72 | 20.5 | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Stakes in other listed companies
At market prices on 28 Oct 2026. Not published: the stakes are worth 0.8% of the company's own market cap, under the 25% this figure is about.
- Its own market capIts own market cap. Closing price × shares in issue.
- ₹344 Cr
- Its stakes, at marketIts stakes, at market. Each stake's per cent × that company's market cap, added up.
- ₹2.60 Cr
- Worth Investment & Trading Co2.70%₹2.60 Cr